Berzosertib (VX-970, M6620) is a first-of-its-kind, potent, selective ATR inhibitor developed by Merck. Ceralasertib (AZD6738) is a selective ATR inhibitor developed by astrazeneca with an IC50 of 1nM. BAY1895344 is a highly effective, highly selective oral ATR inhibitor developed by bayer wit......

Recently, Dr. Shao feng and Dr. Xiaoyun Liu of Peking University School of Basic Medical Sciences published an important new progress in the leading academic journal Nature, revealing a new mechanism by which pathogenic bacteria inhibit pyrodeath in host cells. This discovery adds another milestone ......

The Peking University research team has developed a specific drug for the treatment of COVID-19 and the mechanism of action of the specific drug DXP-604

Azifudine is a class 1 anti-AIDS drug targeting RNA reverse transcriptase. It has good anti-novel coronavirus activity at the cellular and animal levels against COVID-19

Kymera Has announced the results of a trial of kTX-201, a protein inhibitor targeting STAT3 proteins. The results showed that KTX-201 can change the characteristics of tumor microenvironment in a mouse solid tumor model, making tumors more sensitive to PD-1 inhibitors, thus enhancing the effect of P......

If you are looking for a supplier or manufacturer of 7-Bromo-1,1,1-trifluoroheptan-2-one (CAS No.: 647831-24-1) please contact us.